MDT logo

MEDTRONIC PLC

MDTNYSE
๐Ÿ† #116 by market capEarnings Nov 24US Equity
$94.78โ–ฒ $0.83 (+0.88%)
๐ŸŒ™ After hours$95.08โ–ฒ 0.32%Regular close ยท extended-hours price shown
๐Ÿ””
Track MDT
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 0.9%
7dโ–ฒ 1.9%
14dโ–ฒ 0.6%
30dโ–ฒ 5.9%
ytdโ–ผ 1.4%
1yโ–ฒ 1.6%
๐ŸฆMarket Cap
$121.24B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
9.8%
Slowing
๐Ÿ“ŠGross Margin
65.7%
High
๐Ÿ’ตFCF Margin
16.3%
Healthy
โš–๏ธP/S Ratio
3.3x
Fair
Otter Score
84
Strong

Trading Snapshot

Day Range
$93.06 โ€“ $95.72
52-Week Range
$73.31 โ€“ $106.33
Volume (shares)
9,578,572
Avg Volume (shares)
โ€”
Shares Outstanding
1.28B
Next Earnings
2026-11-24

Fundamentals Snapshot

Annual Revenue
$36.36B
Last Q Revenue
$9.76B
P/E Ratio
23.3
P/S Ratio
3.3x
EPS (TTM)
$4.06
Dividend Yield
2.99%
Dilution (1yr)
โˆ’0.2%
MDT logo

MEDTRONIC PLC

MDT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$36.4Bโ–ฒ +8.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
65.0%โ–ผ โˆ’0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
$6.5Bโ–ฒ +8.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$5.4Bโ–ฒ +4.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
1.29Bโ–ผ โˆ’0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$26.5Bโ–ฒ +$1.4B YoY
StockOtter ยท stockotter.space

About MEDTRONIC PLC

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Strong
84/100

Analyst Ratings

โ“˜
Consensus
Buy
33 analysts
Strong Buy9
Buy13
Hold11
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Seeking Alphaยท12h ago

Medtronic: Broader Growth, Attractive Valuation

Medtronic is rated Buy, trading at a 20.8% P/E discount to sector median, with new products driving broader growth post-MiniMed separation. Pulsed field ablation (PFA) and enabling technologies in Cardiovascular and Spin

24/7 Wall Streetยท1d ago

Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks

Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance sheet strength could res

24/7 Wall Streetยท1d ago

Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?

Medtronic just extended a nearly half-century dividend streak, but its raise barely outpaces inflation while rivals like Abbott and J&J grow payouts far faster.

GuruFocusยท6d ago

A Look at Medtronic PLC (MDT) After 3.8% Gain -- GF Value $101.17 vs Price $96.59

On October 22, 2026, Medtronic PLC (MDT) shares rose 3.8% to a current price of $96.59. This movement comes amid a 52-week range of $73.31 to $106.33, indicatin

GlobeNewsWireยท6d ago

Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtueยฎ SAB

NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, โ€œOrchestra BioMedโ€ or the โ€œCompanyโ€), a biomedical company accelerating high-impact technologies to patients through risk-re

PRNewsWireยท6d ago

Medtronic announces positive results from real-world registries for the Sphere-9โ„ข catheter and PulseSelectโ„ข PFA System at APHRS 2026

Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias Medtronic continues to strengthen its position in cardiac ablation, building on a legacy